Pettyjohn Wood & White Inc. Has $896,000 Holdings in Pfizer Inc. (NYSE:PFE)

Pettyjohn Wood & White Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 24.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,766 shares of the biopharmaceutical company’s stock after selling 11,049 shares during the quarter. Pettyjohn Wood & White Inc.’s holdings in Pfizer were worth $896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in PFE. Argyle Capital Management LLC grew its holdings in shares of Pfizer by 5.7% during the 4th quarter. Argyle Capital Management LLC now owns 134,806 shares of the biopharmaceutical company’s stock valued at $3,576,000 after acquiring an additional 7,320 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Pfizer by 1.0% during the fourth quarter. Parkside Financial Bank & Trust now owns 46,491 shares of the biopharmaceutical company’s stock valued at $1,233,000 after purchasing an additional 471 shares during the last quarter. Shoker Investment Counsel Inc. grew its stake in Pfizer by 1.1% in the fourth quarter. Shoker Investment Counsel Inc. now owns 125,442 shares of the biopharmaceutical company’s stock valued at $3,328,000 after purchasing an additional 1,323 shares in the last quarter. Wakefield Asset Management LLLP grew its stake in Pfizer by 6.0% in the fourth quarter. Wakefield Asset Management LLLP now owns 17,401 shares of the biopharmaceutical company’s stock valued at $462,000 after purchasing an additional 985 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in Pfizer by 205.4% in the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 44,900 shares of the biopharmaceutical company’s stock worth $1,191,000 after purchasing an additional 30,200 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE opened at $26.09 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $147.83 billion, a P/E ratio of 18.50, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock’s 50 day moving average price is $26.35 and its two-hundred day moving average price is $27.35.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.